- Our Technology
Controlled delivery for regenerative skin biologics.
ExoGenis is a controlled biologic delivery system designed for predictable
placement of fragile regenerative actives into viable upper skin
for professional dermatology and aesthetic care.
First MVP: exosome-associated biologic formulation for aesthetic recovery and clinic-guided maintenance.
Controlled
upper-skin access
ExoGenis uses short dissolvable microtips designed to create temporary microchannels in the upper skin layers. The system is being developed to support controlled local placement of fragile active formulations without an injection step.
- No retained solid needles
- Controlled microchannel-based access
- Designed for upper-skin interaction
- Compatible with professional clinic workflows
- MVP uses an exosome-associated formulation first
How it works
Apply. Create microchannels. Release. Remove.
APPLY
PATCH
Applied to clean, dry skin as part of a professional or clinic-guided protocol.
.svg)
FORM
MICROCHANNELS
Designed for minimally invasive superficial skin interaction to establish safe delivery paths.
Release
Bioactive Tips
Microtips dissolve during application and release the active formulation locally.
Remove
Backing
The removable backing is taken off after application, with no retained solid needles
Designed for professional
skin workflows
ExoGenis is designed to integrate into post-procedure care pathways and structured clinic protocols.
The pilot kit format is designed to support professional handling, protocol consistency, follow-up, and repeat-use evaluation.
One delivery architecture.Multiple future applications
- Current focus
Regenerative skin biologics
Future expansion
1. Dermatology
2. Post-procedure recovery
3. Advanced biologics
4. Future controlled delivery applications
Not just
microneedle hardware.
A biologic delivery system
built for clinic use.
built for clinic use.
MVP first: exosome-associated formulation for aesthetic recovery and maintenance.
Platform later: additional payloads only after delivery, release, safety, and endpoint evidence.
Dermatology path: advisor-led selection of payload, indication, comparator, and case-study design.
From prototype → clinical adoption
Built on validated technology, now moving into clinical deployment with partner clinics
More than microneedles. A controlled biologic delivery platform built for clinical practice.
MVP & prototyping
Completed
Core delivery system built and functionally validated.
Technical validation
ongoing
Reproducibility, stability, and performance testing ongoing.
Pilot manufacturing
Next
Scale-up and manufacturing readiness in progress.
Clinical pilots
planned
Clinical deployment with partner clinics (2026).
Why our
platform ?
.svg)
Controlled delivery
Clinic-guided workflows
Fragile biologic compatibility
Repeatable administration
Future payload flexibility